Research points towards new blindness prevention methods in diabetic eye disease

By combining data on optometry patient's eyes with advanced computational methods, Indiana University researchers have created a virtual tissue model of diabetes in the eye. The results, reported in the journal PLOS Computational Biology, show precisely how a small protein that can both damage or grow blood vessels in the eye causes vision loss and blindness in people with diabetes. The study … [Read more...]

Detecting diabetic eye disease with machine learning

Diabetic retinopathy — an eye condition that affects people with diabetes — is the fastest growing cause of blindness, with nearly 415 million diabetic patients at risk worldwide. The disease can be treated if detected early, but if not, it can lead to irreversible blindness.  A few years ago, a Google research team began studying whether machine learning could be used to screen for diabetic … [Read more...]

Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models

Experimental and clinical data suggest that pro-angiogenic, pro-inflammatory and mitogenic cytokine leptin can be implicated in ocular neovascularization and the other eye pathologies.  At least in part, leptin action appears to be mediated through functional interplay with vascular endothelial growth factor (VEGF).  The effects of VEGF on leptin expression were assessed in ocular endothelial cell … [Read more...]

Surgeons perform world’s first operation inside the eye using a robot

Robert MacLaren, Professor of Ophthalmology. assisted by Dr Thomas Edwards, Nuffield Medical Fellow, used the remotely controlled robot to lift a membrane 100th of a millimetre thick from the retina at the back of the right eye of the Revd Dr William Beaver, 70, an Associate Priest at St Mary the Virgin, Iffley, Oxford. He is the first patient ever to undergo this experimental procedure. Read the … [Read more...]

Allergan Makes an Eye-Opening Acquisition

Global pharmaceutical company Allergan (NYSE:AGN) may have just revealed its plans for the future.  On Aug. 11, the company announced its plan to acquire ForSight Vision5, a privately held biotech.  Allergan will pay $95 million up front and will also pay a milestone payment next year if ForSight's innovative glaucoma treatment device makes it through the FDA gauntlet and is successfully launched. … [Read more...]

Investigator-Sponsored Phase 2 Study Results Show pSivida’s Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve

WATERTOWN, Mass., July 14, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that the results from an investigator-sponsored Phase 2 study of pSivida’s Medidur showed no recurrence of uveitis in 11 eyes treated with Medidur during the two years following implantation, while … [Read more...]

Prismatic eyewear for patients with tunnel vision to launch

A trio of eyeglasses using revolutionary prism techniques could open up a whole new field of view for patients with hemianopia.  The three designs – yoked prisms in a carrier lens, a bi-part double Fresnel prism, and the mirror-based periscopic prisms – were showcased in the journal Optometry and Vision Science.  Lead researcher and Harvard Medical School ophthalmology professor, Dr Eli Peli, told … [Read more...]

Intraocular therapy prevents or reverses diabetic retinopathy in mice

Pathologic changes of the retina caused by diabetes is the leading cause of blindness in working adults. Diabetic retinopathy has no known cure, treatment options are inadequate, and prevention strategies offer limited protection. In the first of its kind, a report in The American Journal of Pathology describes a potential new intraocular treatment based on manipulating the renin angiotensin … [Read more...]

Retinal Remodeling And Metabolic Alterations in Human AMD

Age-related macular degeneration (AMD) is a progressive retinal degeneration resulting in central visual field loss, ultimately causing debilitating blindness.  While many genetic and environmental risk factors are known for AMD, we currently know less about the mechanisms mediating disease progression.  The goal of this article is to illustrate cell types impacted in AMD and demonstrate the … [Read more...]

EyeCRO data to be presented at ARVO 2016 in Seattle

[Read more...]

Preclinical Ophthalmic Contract Research